THE ARISING · Markets & Strategy
Experimental Cell Therapy Shows a Walking Signal in a Small Frailty Trial
The difference emerged at nine months. The direct dose-versus-placebo comparisons had not reached statistical significance at six months.
A phase 2b trial randomly assigned 148 ambulatory older adults with frailty to different doses of an investigational cell therapy, laromestrocel, or placebo. The main measure was how far participants could walk in six minutes.
At six months, no single dose showed a statistically significant difference from placebo, although a separate prespecified analysis found that walking performance improved more as the dose increased. By nine months, the highest-dose group had improved by 63.4 meters more than placebo (95% confidence interval, 17.1 to 109.6 meters). At that visit, the walking results for those groups were based on 15 participants receiving the highest dose and 26 receiving placebo.
Serious events were comparable across groups in this small study. Two participants died, one in a treatment group and one in the placebo group; investigators did not attribute serious events to the product. The trial found no statistically significant differences in falls, fractures or hospitalizations. The walking result warrants a larger trial, but it is not proof that the therapy prevents disability, reverses frailty or extends life.
The two analyses at six months asked different questions. The direct comparison asked whether any individual dose clearly beat placebo. The dose-response analysis looked for a pattern across groups. The later result is encouraging because walking is a practical measure of function, but a short walking test cannot substitute for evidence about maintaining independence. Larger studies need to show whether patients walk farther in daily life and whether any benefit lasts.